KTKeisuke Takahata

Keisuke Takahata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Keisuke Takahata has a total of 212 co-authors. Here are the top co-authors by number of shared publications:

  • Makoto Higuchi

    Advanced Neuroimaging Center, Institute for Quantum Medial Science National Institutes for Quantum Science and Technology (QST) Chiba Japan

    19 shared publications
  • Kenji Tagai

    Advanced Neuroimaging Center, Institute for Quantum Medial Science National Institutes for Quantum Science and Technology (QST) Chiba Japan

    18 shared publications
  • Hironobu Endo

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan

    16 shared publications
  • Yasuharu Yamamoto

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum and Radiological Science and Technology

    13 shared publications
  • Kiwamu Matsuoka

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan

    12 shared publications
  • Manabu Kubota

    Advanced Neuroimaging Center Institute for Quantum Medical Science National Institutes for Quantum Science and Technology Chiba Japan

    12 shared publications

Latest Publications

  • In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy

    by Yuko Kataoka, Ryoji Goto, Yoshikazu Chishiki, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Sho Moriguchi, Yuki Momota, Tetsuji Kamada, et al.

  • Open Access

    From Lesion Network Mapping in Humans to Causal Circuit Validation in Animals for Defining Neuromodulation Targets: A Narrative Review

    by Amaki Tsukazaki, Koki Takahashi, Shinichiro Nakajima, Yu Mimura, Keita Taniguchi, Saki Homma, Sakiko Tsugawa, Keisuke Takahata, Hironobu Endo, Makoto Higuchi, et al.

    Neuromodulation techniques, such as repetitive transcranial magnetic stimulation (rTMS), have demonstrated efficacy across several neuropsychiatric disorders, yet identifying symptom-specific and biologically informed stimulation targets remains a major challenge. Lesion network mapping (LNM) addresses this problem by treating focal brain lesions as natural perturbations and mapping anatomically heterogeneous lesion locations onto normative connectomes to identify convergent symptom-relevant circuits. Since its introduction in 2015, LNM has generated candidate neuromodulation targets across diverse neurological and psychiatric conditions, with several studies showing overlap between lesion-derived networks, independent neuroimaging findings, and therapeutic neuromodulation targets. However, these observations do not establish whether the identified networks connected to lesion sites are causally responsible for symptom expression or how they should be therapeutically modulated. Because LNM relies on correlation-based connectivity measures, it cannot determine which circuit components or pathways causally mediate the relevant symptom, or whether candidate neuromodulation targets should be activated or inhibited. We therefore propose a translational framework in which LNM-derived circuit hypotheses are examined through cross-species anatomical and functional mapping, region-, cell-, and projection-specific perturbation in animal models, and concurrent behavioral and whole-brain functional readouts, before clinical evaluation. This framework positions LNM as a tool for identifying candidate circuits that are first tested in animal models for causal relevance and perturbation direction, and then evaluated clinically for therapeutic relevance.

  • Open Access

    Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau ( 18F ) Positron Emission T omography

    by Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, et al.

    Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high‐contrast in vivo detection of four‐repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: Twenty‐six patients with PSP (18 Richardson's syndrome [PSP‐RS], 8 non‐RS) and 10 age‐ and sex‐matched healthy controls (HCs) underwent florzolotau PET, magnetic resonance imaging, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVRs) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellar white matter, and minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP‐RS and a univariate correlation (Spearman's ρ = 0.688, P = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to increase with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau‐targeted therapeutic trials. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Postmortem Alterations of Metabotropic Glutamate Receptors across Neuropsychiatric Disorders: A Systematic Review

    by Ryoma Kani, Tony Kaku, Yu Arai, Takahide Etani, Sunjun Huh, Keisuke Saito, Saki Homma, Koki Takahashi, Masataka Wada, Yasuharu Yamamoto, et al.

    Metabotropic glutamate receptors (mGluRs) regulate glutamatergic transmission and have been implicated in diverse neuropsychiatric disorders, but human postmortem evidence remains fragmented. We aimed to map these findings across diagnoses, receptor subtypes, brain regions, and measurement modalities. Following PRISMA guidelines, we systematically searched MEDLINE, EMBASE, and Web of Science from inception to August 8, 2026, for studies assessing GRM transcripts, as well as mGluR protein abundance, localization, assembly, or receptor binding in human postmortem brain tissue. Of 532 records identified, 57 reports met eligibility criteria. Findings were synthesized narratively because of substantial heterogeneity in diagnoses, brain regions, receptor subtypes, and assays. Postmortem evidence was concentrated on mGluR5, mGluR2/3, and mGluR1, and on the prefrontal cortex, anterior cingulate cortex, and hippocampus. mGluR-related alterations were reported across disorders, including schizophrenia, major depressive disorder, Alzheimer disease, autism spectrum disorder, and alcohol use disorder. Although most analyses yielded null findings, the direction and magnitude of mGluR alterations varied across brain regions, receptor subtypes, and molecular endpoints. This inconsistency may partly reflect the distinct biological levels captured by transcript abundance, total protein, receptor assembly, localization, and ligand binding, together with regional, cell-type, disease-stage, and clinical heterogeneity. The available evidence therefore suggests context-dependent alterations in mGluR biology but not a uniform or disorder-specific molecular signature. Integration of postmortem findings with other approaches, including in vivo imaging, may clarify their biological and clinical significance.

  • Open Access

    High prevalence of tau pathologies in late-onset psychosis: A PET study

    by Manabu Kubota, Shin Kurose, Kenji Tagai, Yuki Momota, Masanori Ichihashi, Hironobu Endo, Chie Seki, Sho Moriguchi, Yasuharu Yamamoto, Yuko Kataoka, et al.

    Late-onset psychosis (LOP) exhibits distinct clinical features compared with younger-onset psychosis. Although postmortem and epidemiological studies have suggested an association between LOP and neurodegenerative processes, particularly tauopathies, in vivo evidence remains limited. This study aimed to investigate the involvement of Alzheimer’s disease (AD) and non-AD tauopathies in LOP using amyloid PET and tau PET with florzolotau (18F) ( 18 F-florzolotau; also known as 18 F-APN-1607 or 18 F-PM-PBB3), a tracer capable of detecting a broad range of tau pathologies. Thirty-seven patients with LOP and 47 age-matched controls underwent PET scans with 11 C-PiB and 18 F-florzolotau to assess group differences in amyloid beta (Aβ) and tau accumulation. Diagnostic effects on regional 18 F-florzolotau standardized uptake value ratios (SUVRs) were assessed. Associations between regional SUVRs and cognitive and clinical features were examined separately in Aβ-positive and Aβ-negative subgroups. Patients exhibited significantly higher positivity rates for both Aβ (13 of 37 patients, 35.1%) and tau (24 patients, 64.9%) than controls (one of 47 controls, 2.1% for Aβ and seven controls, 14.9% for tau). A significant diagnostic effect was observed on regional 18 F-florzolotau SUVRs ( P = 0.004), with post-hoc analyses revealing increased tracer retention in the parietal cortex. This diagnostic effect remained robust when the analysis was restricted to Aβ-negative participants ( P = 0.002). Among Aβ-positive patients, greater parietal tau burden was associated with lower Frontal Assessment Battery scores. In conclusion, this in vivo PET study demonstrated a high prevalence of AD-like and non-AD-like tau accumulation patterns in LOP, suggesting that LOP may be associated with heterogeneous tau-related neurodegenerative processes.


  • Open Access

    Remote network for cognitive symptoms derived from tau accumulation in progressive supranuclear palsy

    by Yuki Hori, Hironobu Endo, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Shin Kurose, Yuki Momota, Naomi Kokubo, Chie Seki, Sho Moriguchi, et al.

    Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with motor and cognitive impairments. Whereas motor symptoms are associated with subcortical tau deposits, the mechanisms underlying the cognitive symptoms remain unclear due to heterogeneous and primarily subcortical distribution of pathological tau deposits. Here, we combined tau-PET (tau positron emission tomography) using a high-contrast probe we developed with a normative connectome in 37 patients with PSP and 48 healthy controls. We found that tau deposition sites functionally connected to a common cortical network that could not be derived from atrophy. This network predominantly overlapped with canonical action-mode and frontoparietal networks, which support adaptive, goal-directed behavior. Whereas the extent of primary tau deposition predicted motor symptoms, the normative connectivity strength from tau deposition sites to the identified cortical network explained the severity of cognitive deficits. These findings suggest a previously unknown mechanism that cognitive, but not motor, deficits in PSP arise from remote effects of tau deposition—independent of atrophy—via convergent connectivity to a common cortical network.


  • Open Access

    Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET

    by Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, et al.

    Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.

  • Open Access

    A Cautionary Note on the Indication for Deep Brain Stimulation in Parkinsonism Patients With SLC9A6 Gene Mutations

    by Shohei Okusa, Toshiki Tezuka, Kenzo Kosugi, Yasuharu Yamamoto, Keisuke Takahata, Makoto Higuchi, Takenori Akiyama, Masahito Kobayashi, Masahiro Toda, Daisuke Ito, et al.


  • Open Access

    Impact of brain damage on moral judgment

    by Miho Suganami, Keisuke Takahata, Yu Mimura, Masahiro Yamamoto, Hiroyuki Uchida, Taro Muramatsu, Masaru Mimura

    Aim: This study aimed to determine the effects of damage to various brain regions on moral judgment using a novel third‐party punishment task with fully manipulated conditions.Methods: We assessed 35 individuals with brain damage (26 with frontal lobe and nine with non‐frontal lobe damage) and 30 healthy controls (HCs) using a moral judgment task consisting of 40 vignettes across five conditions, with varying degrees of intentionality and consequences. Participants rated the protagonist's “badness” and their aroused feelings. Cognitive impairments and empathetic traits were also assessed.Results: Compared to HCs, individuals with brain damage judged protagonists to be more blameworthy than did HCs in vignettes where harmful intentions were absent (No Negligence, p = 0.02; No Harm, p = 0.02). The order of moral judgment ratings across conditions was consistent between groups, indicating preserved knowledge of social/moral norms in brain‐damaged individuals. Although these are preliminary results, there are no significant differences in moral judgment ratings between individuals with frontal and non‐frontal lobe damage.Conclusion: This study revealed that individuals with damage to diverse brain regions show excessive punitive tendencies toward the actions of others without malicious intention. These effects cannot be fully explained by changes in empathy or emotional responses. Moral judgment ratings did not significantly differ between individuals with frontal and non‐frontal lobe damage. However, given the small sample size of the non‐frontal lesion group, these findings should be interpreted with caution, and further research is necessary to confirm this conclusion.


  • Concurrent Alzheimer's disease pathologies in Lewy body diseases affect cognition and glucose metabolism in the posterior cingulate gyrus: A multimodal PET study

    by Kosei Nakamura, Kenji Tagai, Hitoshi Shinotoh, Shigeki Hirano, Soichiro Kitamura, Hironobu Endo, Keisuke Takahata, Yuhei Takado, Ming-Rong Zhang, Kazunori Kawamura, et al.

    Background: Lewy body disease (LBD) is a neurodegenerative disease characterized by Lewy bodies, and it clinically presents dementia with Lewy bodies (DLB) and Parkinson's disease (PD). Alzheimer's disease (AD) pathologies frequently coexist with LBD, complicating the clinical manifestation. Objective: We evaluated the impact of AD pathologies, including amyloid-β and tau depositions, on cognitive dysfunction and glucose metabolism in LBD using multiple positron emission tomography scans. Methods: Our study cohort consisted of 14 patients diagnosed with LBD, including five from the PD spectrum and nine from the DLB spectrum. In addition, 12 amyloid-negative cognitively healthy controls (HCs) and 13 amyloid-positive AD-spectrum patients were included. We subsequently explored the influence of amyloid and tau deposition on cognitive dysfunction and glucose metabolism among the LBD patients. Results: In the LBD group, 44.4% of the DLB patients were amyloid-positive, and all PD patients were amyloid-negative. While tau accumulation was lower than in AD and similar to HCs at the group level, tau accumulation in the AD signature region was correlated with cognitive dysfunction. Among the changes in glucose metabolism, the cingulate island sign (CIS) index was elevated compared to AD. However, as cognitive impairment progressed, the CIS index decreased, reflecting reduced metabolism in the posterior cingulate gyrus, which was closely associated with tau accumulation in the same region. Conclusions: Our findings indicate that AD pathologies, and particularly tau accumulation, significantly impact both cognitive dysfunction and glucose metabolism in LBD. This underscores the importance of addressing AD-related changes in the clinical management of LBD patients.